Profectus Biosciences is a research and development company dedicated to harnessing the immune system to treat and prevent viral diseases and cancers through the delivery of our proprietary prime/boost vaccines and small molecules. Click here for more information on Profectus’s programs.

March 2, 2010: Ichor Medical Systems and Profectus Biosciences Enter into an Agreement for Use of TriGridTM Electroporation Device to Develop Multiple DNA Vaccines. Learn More >

January 7, 2010: Profectus BioSciences, Inc. to present at key investor conference in January 2010. Learn More >

August 25, 2009: Profectus BioSciences, Inc. enters into research collaboration agreement with the PATH Malaria Vaccine Initiative(MVI). Learn More >

July 22, 2009: Profectus BioSciences, Inc. secures $5M in Series C Venture Funding. Learn More >

July 20, 2009: Empire State Development Attracts Profectus BioSciences to NY. Learn More >